Since the lysis module enables engineered bacteria to release various payloads in tumor grafts50, as a prototype validation, two additional therapeutic strains based on pLldR-regulated lysis strains were constructed to activate host immune response (mouse CCL21)51 or initiate programmed cell death in tumor cells (CDD-iRGD)52. The gene discussed is CCL21; the disease is neoplasm.